The University of Southampton
University of Southampton Institutional Repository

Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans

Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans
Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans

Plasmodium falciparum transmission-blocking vaccines (TBVs) targeting the Pfs25 antigen have shown promise in mice but the same efficacy has never been achieved in humans. We have previously published pre-clinical data related to a TBV candidate Pfs25-IMX313 encoded in viral vectors which was very promising and hence progressed to human clinical trials. The results from the clinical trial of this vaccine were very modest. Here we unravel why, contrary to mice, this vaccine has failed to induce robust antibody (Ab) titres in humans to elicit transmission-blocking activity. We examined Pfs25-specific B cell and T follicular helper (Tfh) cell responses in mice and humans after vaccination with Pfs25-IMX313 encoded by replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA) delivered in the heterologous prime-boost regimen via intramuscular route. We found that after vaccination, the Pfs25-IMX313 was immunologically suboptimal in humans compared to mice in terms of serum Ab production and antigen-specific B, CD4+ and Tfh cell responses. We identified that the key determinant for the poor anti-Pfs25 Ab formation in humans was the lack of CD4+ T cell recognition of Pfs25-IMX313 derived peptide epitopes. This is supported by correlations established between the ratio of proliferated antigen-specific CD4+/Tfh-like T cells, CXCL13 sera levels, and the corresponding numbers of circulating Pfs25-specific memory B cells, that consequently reflected on antigen-specific IgG sera levels. These correlations can inform the design of next-generation Pfs25-based vaccines for robust and durable blocking of malaria transmission.

CD4+, P. falciparum, Pfs25, transmission blocking, vaccine
1664-3224
732667
Zaric, Marija
766af893-ebaa-49ef-a8e9-51d43e723d0c
Marini, Arianna
40d5d151-4bed-4b04-9e7b-cadd462f107c
Nielsen, Carolyn M
b4efeed7-92bc-4616-bd2f-92ce5aba55ff
Gupta, Gaurav
98895f74-a842-44b9-a4c1-66e452961670
Mekhaiel, David
4f5a9cf8-4824-4a93-bf23-9dd77c186d4a
Pham, Thao P
56aa740b-cde4-426b-b72b-bdfed8292ddd
Elias, Sean C
28d2a036-b258-40e2-a405-fd82219e6128
Taylor, Iona J
07f0b28b-3c05-4af6-a00e-d471e3ab43f1
de Graaf, Hans
447e78ed-346f-45bb-9238-fce2118d5559
Payne, Ruth O
af14315a-cd57-4c77-b2bc-4d03d0daf6d7
Li, Yuanyuan
4909cd54-328f-4058-93a9-ea3e53c69826
Silk, Sarah E
58987ae6-e5dc-4008-a36b-8c2a7b66ab61
Williams, Chris
23264ea2-3d66-436d-84a1-8fcd4aa97f66
Hill, Adrian V S
1d0fcf95-c251-4317-b4b9-f93db4cb8806
Long, Carole A
0a762300-9d7a-47d0-b086-78676f736540
Miura, Kazutoyo
37aa1488-b065-4302-b465-25b2c6dcb5b1
Biswas, Sumi
ac3e43ac-7cb7-4024-986f-6ec503e7fcae
Zaric, Marija
766af893-ebaa-49ef-a8e9-51d43e723d0c
Marini, Arianna
40d5d151-4bed-4b04-9e7b-cadd462f107c
Nielsen, Carolyn M
b4efeed7-92bc-4616-bd2f-92ce5aba55ff
Gupta, Gaurav
98895f74-a842-44b9-a4c1-66e452961670
Mekhaiel, David
4f5a9cf8-4824-4a93-bf23-9dd77c186d4a
Pham, Thao P
56aa740b-cde4-426b-b72b-bdfed8292ddd
Elias, Sean C
28d2a036-b258-40e2-a405-fd82219e6128
Taylor, Iona J
07f0b28b-3c05-4af6-a00e-d471e3ab43f1
de Graaf, Hans
447e78ed-346f-45bb-9238-fce2118d5559
Payne, Ruth O
af14315a-cd57-4c77-b2bc-4d03d0daf6d7
Li, Yuanyuan
4909cd54-328f-4058-93a9-ea3e53c69826
Silk, Sarah E
58987ae6-e5dc-4008-a36b-8c2a7b66ab61
Williams, Chris
23264ea2-3d66-436d-84a1-8fcd4aa97f66
Hill, Adrian V S
1d0fcf95-c251-4317-b4b9-f93db4cb8806
Long, Carole A
0a762300-9d7a-47d0-b086-78676f736540
Miura, Kazutoyo
37aa1488-b065-4302-b465-25b2c6dcb5b1
Biswas, Sumi
ac3e43ac-7cb7-4024-986f-6ec503e7fcae

Zaric, Marija, Marini, Arianna, Nielsen, Carolyn M, Gupta, Gaurav, Mekhaiel, David, Pham, Thao P, Elias, Sean C, Taylor, Iona J, de Graaf, Hans, Payne, Ruth O, Li, Yuanyuan, Silk, Sarah E, Williams, Chris, Hill, Adrian V S, Long, Carole A, Miura, Kazutoyo and Biswas, Sumi (2021) Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans. Frontiers in Immunology, 12, 732667, [732667]. (doi:10.3389/fimmu.2021.732667).

Record type: Article

Abstract

Plasmodium falciparum transmission-blocking vaccines (TBVs) targeting the Pfs25 antigen have shown promise in mice but the same efficacy has never been achieved in humans. We have previously published pre-clinical data related to a TBV candidate Pfs25-IMX313 encoded in viral vectors which was very promising and hence progressed to human clinical trials. The results from the clinical trial of this vaccine were very modest. Here we unravel why, contrary to mice, this vaccine has failed to induce robust antibody (Ab) titres in humans to elicit transmission-blocking activity. We examined Pfs25-specific B cell and T follicular helper (Tfh) cell responses in mice and humans after vaccination with Pfs25-IMX313 encoded by replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA) delivered in the heterologous prime-boost regimen via intramuscular route. We found that after vaccination, the Pfs25-IMX313 was immunologically suboptimal in humans compared to mice in terms of serum Ab production and antigen-specific B, CD4+ and Tfh cell responses. We identified that the key determinant for the poor anti-Pfs25 Ab formation in humans was the lack of CD4+ T cell recognition of Pfs25-IMX313 derived peptide epitopes. This is supported by correlations established between the ratio of proliferated antigen-specific CD4+/Tfh-like T cells, CXCL13 sera levels, and the corresponding numbers of circulating Pfs25-specific memory B cells, that consequently reflected on antigen-specific IgG sera levels. These correlations can inform the design of next-generation Pfs25-based vaccines for robust and durable blocking of malaria transmission.

Text
fimmu-12-732667 - Version of Record
Available under License Creative Commons Attribution.
Download (10MB)

More information

Accepted/In Press date: 7 September 2021
Published date: 30 September 2021
Keywords: CD4+, P. falciparum, Pfs25, transmission blocking, vaccine

Identifiers

Local EPrints ID: 453259
URI: http://eprints.soton.ac.uk/id/eprint/453259
ISSN: 1664-3224
PURE UUID: 9766d1e9-9498-4bef-8ae9-f50de2ddd268

Catalogue record

Date deposited: 11 Jan 2022 17:48
Last modified: 16 Mar 2024 14:47

Export record

Altmetrics

Contributors

Author: Marija Zaric
Author: Arianna Marini
Author: Carolyn M Nielsen
Author: Gaurav Gupta
Author: David Mekhaiel
Author: Thao P Pham
Author: Sean C Elias
Author: Iona J Taylor
Author: Hans de Graaf
Author: Ruth O Payne
Author: Yuanyuan Li
Author: Sarah E Silk
Author: Chris Williams
Author: Adrian V S Hill
Author: Carole A Long
Author: Kazutoyo Miura
Author: Sumi Biswas

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×